SHANGHAI, China, April 10, 2026 – Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
Proceeds will be strategically allocated to accelerate Oricell’s global expansion and clinical development, while strengthening its technological capabilities and paving the way to upcoming capital market milestones.
As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo(Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.
OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.
Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.
Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: "This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena."
Mr. Shan Fu, Managing Partner at Vivo Capital, commented:"While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry's toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated 'Platform and Pipeline' strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell’s expansion into international markets."
Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: “As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide.”
About Oricell Therapeutics
Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Powered by a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies. This technical prowess and global strategy are exemplified by the development of another core candidate, OriCAR-017. Supported by compelling data from IIT in China, the program paved the way into global development, rapidly securing IND approvals from both China NMPA and US FDA, along with FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD). OriCAR-017 has demonstrated a favorable safety profile and robust efficacy in both IIT and registrational clinical trials, with data featured at leading global conferences including 2022 ASCO, 2022 EHA, 2024 ASCO, and published in top-tier academic journals The Lancet Haematology. These milestones underscore Oricell’s capabilities in regulatory strategy, clinical development, and global execution, reflecting its commitment to transforming the future of cell therapy and delivering new hope to patients worldwide. For more information, please visit: www.oricell.com.
About Vivo Capital
Vivo Capital is a premier global healthcare investment firm with a 30-year track record of building transformative companies. Since its founding in 1996, Vivo has evolved into a comprehensive investment platform spanning venture capital, growth equity, buyouts, and public markets. Managing $7.5 billion in assets across 16 USD and RMB funds, the firm has cultivated a portfolio of over 460 innovative companies worldwide. Vivo’s strategy goes beyond capital; it leverages a deeply integrated ecosystem to provide strategic operational support and resource connectivity to its partners. With an exclusive focus on the healthcare sector—ranging from biotech and pharma to devices and services—Vivo targets high-growth opportunities in the world’s most critical markets. Headquartered in Palo Alto, California, Vivo operates with a lean, expert team of over 70 professionals, maintaining key hubs in Beijing, Shanghai, Hong Kong, Taipei, and Singapore to bridge global innovation with local execution.
About Beijing Medical and Health Care Industry Investment Fund
Beijing Medical and Health Care Industry Investment Fund is managed by Beijing Shunxi Private Fund Management Co., Ltd. (“Shunxi Fund”), a full-lifecycle investment platform under Beijing State-owned Capital Operation and Management Co., Ltd. (BSCOMC). Shunxi Fund focuses on strategic emerging sectors—particularly biopharma and healthcare—and has evolved from its original mandate of “investing early, small, in technology, and in Beijing” into a comprehensive investor across the innovation lifecycle. Through partnerships with top universities, research institutes, municipal/state-owned funds, leading industry players, government agencies, and market-driven GP collaborators, Shunxi has built a multi-dimensional ecosystem that delivers unique deal flow and robust post-investment value creation.
About Qiming Venture Partners
Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.
About E-Town Capital
E-Town Capital is a leading state-owned investment platform dedicated to advancing Beijing’s economic development through strategic investments in high-growth sectors. The firm focuses on biotechnology and healthcare, next-generation information technology, new energy intelligent vehicles, and robotics, operating across four core business lines: industrial investment, fund management, technology finance, and IT infrastructure innovation.
As of September 2025, E-Town Capital manages over 90 funds with RMB 60 billion in paid-in capital and a total fund size exceeding RMB 1 trillion, supporting 280+ investment projects across Beijing’s innovation ecosystem. Its portfolio drives technological advancement while directly contributing to the city’s strategic economic goals.
About Luxin Venture Capital
Luxin Venture Capital Group Co., Ltd. (SHSE: 600783) stands as a dominant force in China’s private equity landscape. Controlled by the state-owned Shandong Luxin Investment Holding Group, Luxin holds the distinction of being the first venture capital firm to list on mainland China’s domestic capital markets. Over its two-decade history, the firm has scaled its operations significantly, currently managing more than 40 funds with approximately 20 billion yuan ($2.8 billion) in assets under management. Its investment thesis targets high-growth sectors critical to China’s economic transition, including healthcare, advanced manufacturing, electronics, new energy, and new materials.
About Elikon Venture
Founded in 2021, Elikon Venture is a specialized early-stage venture firm focused exclusively on biomedical innovation. The firm partners with entrepreneurs developing proprietary IP and globally competitive technologies to address unmet clinical needs, accelerating the development of therapeutics that deliver measurable clinical outcomes and improve patient health.
About Talon Capital
Headquartered in Hong Kong, Talon Capital is the private equity investment division of Wealth Harbour Investment & Management Co., Limited, an SFC licensed corporation in Hong Kong. It invests in core sectors including technology, healthcare, business services and consumer in Asia across the company lifecycle primarily from growth to mid-market stage. By adhering to an investment philosophy that places company quality at the center and a founder-to-founder approach at the heart of value creation, Talon Capital partners with outstanding businesses to drive sustainable growth and achieve superior return.
Forward-Looking Statements
This press release contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited (“the Company” or “Oricell”). The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
沪公网安备 31011502019994号